MedTrace Logo

Effect of Rosuvastatin and Eicosapentaenoic Acid on Neoatherosclerosis: The LINK-IT Trial

NCT03192579 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-01-09

No results posted yet for this study

Summary

This study aim to evaluate whether intensive lipid lowering therapy may improve the clinical outcomes in coronary artery disease patients with in-stent neoatherosclerosis, in comparison with standard therapy.

Conditions

  • Coronary Artery Disease Progression

Interventions

DRUG

EPA and high dose rosuvastatin

After randomization, patients with intensive lipid lowering therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for 12 months.

DRUG

Standard dose rosuvastatin

After randomization, patients with standard lipid lowering therapy start only rosuvastatin (2.5mg/day) for 12 months.

Sponsors & Collaborators

  • Kobe University

    lead INDUSTRY

Principal Investigators

  • Hiromasa Otake, ph.D · Kobe University Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-26
Primary Completion
2017-06-02
Completion
2017-06-02

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03192579 on ClinicalTrials.gov